Data-Driven Drug Development: Accelerating Small Molecule Success in Early Phase

The development of small-molecule therapeutics has never been more complex. Pharmaceutical researchers are faced with molecules with higher molecular weight and increasing 3D character. At the same time, regulatory expectations are rising, market competition is intensifying, and patient needs demand more rapid development timelines. In this context, leveraging early-phase, data-driven strategies is essential for accelerating drug development while mitigating risk.

LATEST VIDEO

Latest news

26th November 2025

FDA Grants Otsuka Accelerated Approval for IgAN Treatment

26th November 2025

EU Approves Regeneron and Sanofi’s Dupixent for Chronic Spontaneous Urticaria

21st November 2025

Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand

20th November 2025

Antheia and TAPI Partner to Advance Global Commercialization Strategy for Critical Pharmaceutical Ingredients

19th November 2025

Novartis announces plans to build flagship manufacturing hub in North Carolina

19th November 2025

Piramal Pharma Solutions’ Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates

19th November 2025

Inizio Evoke launches Predictev™, a query-driven predictive intelligence engine for life-sciences commercial teams

17th November 2025

Johnson & Johnson to Acquire Halda Therapeutics for $3.05 Billion

17th November 2025

First Pertzumab Biosimilar Receives FDA Approval

17th November 2025

Almac announces multi-million-pound investment in Singapore

14th November 2025

Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal

This week’s featured articles

CDMO Partnerships Built on Flexibility, Innovation, Strategic Investment, Sustainability & True End-to-End Support

Large Language Models and Beyond: AI’s Impact on Clinical Trial Efficiency and Integrity

Innovation in mAb purification using affinity chromatography resins based on proprietary rProtein A

Unpacking Global Biopharma Business Relations with Ashu Tandon

A surprising comparison between CDMOs and auto makers

Partnered with top industry events and organisations